Anti-Human CD30 Ligand (Clone 116614)

Purified Recombinant Human CD30 Ligand (Accession # P32971)

This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.

The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Neutralization: This antibody is useful for neutralization of Human CD30 Ligand bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Human CD30 Ligand (at 1.0 ng/ml) is 1.0-4.0 µg/ml.

Mouse Anti-Human CD30 Ligand (Clone 116614) recognizes an epitope on Human CD30 Ligand. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. This antibody showed no cross-reactivity with rhCD27 Ligand, rmCD30 Ligand or rhCD40 Ligand.

The CD30 ligand is a type II transmembrane glycoprotein of the tumor necrosis factor ligand superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. Recombinant CD30L has been shown to co-stimulate T cells and to act as a mitogen for Hodgkin's disease derived cell lines. The receptor for CD30L, CD30/ TNFRSF8/CD153, is a type I cytokine receptor that is highly expressed by activated T cells, Hodgkin and Reed- Sternberg (H-RS) cells, and anaplastic large cell lymphoma cells. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis.

1. Croager, EJ. et al. (1997) Biochim. Biophys. Acta. 1353:231
2. Gruss, HJ. et al. (1994) Blood 83:1521
3. Wendtner, CM. et al. (1995) Cancer Res. 55:4157
4. Fischer, M. et al. (2006) J. Clin. Invest. 116:2748
5. Blazar, BR. et al. (2004) J. Immunol. 173:2933